



Gen AI-powered research tasks in biotech

Your Bridge between Gen AI productivity and
Life Science Innovation.

Our mission:

30% R&D productivity
gains using generative AI



Problem

Generative AI will **transform R&D** workflows, problem solving by researchers, and discovery & design.

But:

- 1 Biotech SMEs are **constrained on resources** to develop & integrate.
- 2 **Data quality** is a concern for 80% of biotech teams¹.
- 3 The **security** of Cloud-based AI is a red flag for 80% of biotechs².
- 4 Generic AI applications **do not translate well** to biotech use cases.

Solution

Empowering biotech teams with a **tailored Gen AI suite** to break through constraints, streamline workflows, and unlock unprecedented productivity with intelligent automation and AI-driven insights.




**Time-Saving
Workflow AI**
Specialized for
research tasks



**Embedding &
SLMs for**
rapid, precise
contextual
understanding



**Secure On-
Premise AI**
Protects IP and
secures privacy



**Collaborative
dashboard**
Enhances team
efficiency

Market Validation

- Value per customer validated at >€30,000 per year
- Validated price first offering at €1,000 (single use case)

Current validation in the market:

- Current offering: IntelliBio has developed 3x AI agents (MVP)
- Sales; Grant Genie at €1,500 (3 sales with 50% discount)

Paying customers:



Market Size


The value of Generative AI within biotech will shortly exceed the (€38B) SaaS for biotech market.



Gen AI-driven **productivity** to add €21B value to biotech by 2025



Initial target market is 2,300 **biotech SMEs** in Europe.



Value per customer validated at >€30,000 per year.

Product

"Our AI-powered platform leverages embeddings and Small Language Models (SLMs) to deliver secure, on-premise solutions that empower biotech teams to accelerate research, automate workflows, and unlock faster innovation with unparalleled productivity."



Business Model

IntelliBio intends to operate as a AI-a-a-S business.

- **Launch Grant Genie:** Establish market presence & initial revenue.
- **Develop On-Prem PoC:** Validate with biotech SMEs.
- **Expand offering of AI agents:** Develop modular AI capabilities.
- **Scale Operations:** Use follow-up funding to expand products.
- **Build AI Suite:** Offer €30k–€100k/year modular solutions.

Competition

By addressing gaps in data privacy, integration complexity, and cost-effectiveness, our AI-powered platform provides secure solutions with customizable tools designed for their unique research needs.

Advantages

- Comprehensive all-in-one platforms (e.g. Benchling).
- Foundational model R&D (e.g., DeepMind).
- Cloud Accessibility & Seamless remote collaboration.

Disadvantages

- Data Privacy Concerns: Limited security for sensitive data.
- High Costs: Expensive for smaller biotech firms.
- Rigid AI Tools: Limited customization for workflows.

Our Team



Dr. Boaz van Driel CEO & co-founder



Leonard Gonsalves CTO & co-founder



Enrico Maset
Advisor & Partner

Our Founding Team:

Bridging Life Science
Innovation with Technological
Excellence

Our Partner:

Leveraging
funding for rapid
growth.

Testimonials

Our customers recognize our long-term potential and short-term value.

“You need a respectable biotech to work with as launching customer, I think my new venture Gyes BV can be that.”

– Ton Logtenberg, ex-CEO Merus

“... Profs here [] all are very excited to try [Grant Genie] ...!”

- Neuroscience prof. at ETH (Swiss)

“That is really good quality, only needed a few edits.”

– Fred Vaz, Director metabolomics lab

Financial Model

We generate revenue through a subscription-based model with modular upselling for additional AI capabilities, complemented by on-premise AI deployments supplied via trusted third-party vendors.





Thank You

Further contact:

Boaz van Driel, PhD | CEO IntelliBio BV
boazceo@intellibio.tech
+31 6 53715300